Ruxolitinib, oo sidoo kale loo yaqaan ruxolitinib ee Shiinaha, waa mid ka mid ah "daawoyinka cusub" ee si weyn loogu taxay tilmaamaha bukaan-socodka ee daaweynta cudurrada dhiig-baxa sannadihii la soo dhaafay, waxayna muujisay waxtarka rajo-gelinta cudurrada myeloproliferative.
Daawada la beegsaday ee Jakavi ruxolitinib waxay si wax ku ool ah u joojin kartaa firfircoonida kanaalka JAK-STAT oo dhan waxayna yaraynaysaa calaamada aan caadiga ahayn ee kanaalka, sidaas darteed lagu gaaro waxtarka. Waxa kale oo loo isticmaali karaa daaweynta cudurro kala duwan, iyo JAK1 cilladaha aan caadiga ahayn ee goobta.
Ruxolitinibwaa kinase inhibitor lagu tilmaamay daawaynta bukaanada qaba myelofibrosis dhexe ama khatar sare, oo ay ku jiraan myelofibrosis aasaasiga ah, post-geniculocytosis myelofibrosis, iyo post-primary trombocythemia myelofibrosis.
Daraasad caafimaad oo la mid ah (n = 219) bukaanno la kala soocay oo leh dhexdhexaad-khatar-2 ama halis sare MF, bukaanada qaba MF ka dib erythroblastosis run ah, ama bukaanada qaba MF ka dib thrombocytosis aasaasiga ah ee laba kooxood, mid qaata ruxolitinib afka 15 ilaa 20 mgbid (n=146) iyo kan kale oo hela daawada xakamaynta togan (n=73). Qodobbada asaasiga ah iyo kuwa ugu muhiimsan ee daraasadda waxay ahaayeen boqolleyda bukaannada leh ≥35% hoos u dhigista mugga beeryarada (oo lagu qiimeeyay sawirka magnetic resonance imaging ama sawir-gacmeed) toddobaadyada 48 iyo 24, siday u kala horreeyaan. Natiijooyinku waxay muujiyeen in boqolkiiba bukaannada leh in ka badan 35% hoos u dhigista mugga beeryarada laga soo bilaabo bilowga usbuuca 24 waxay ahayd 31.9% kooxda daaweynta marka la barbar dhigo 0% kooxda kantaroolka (P <0.0001); iyo boqolleyda bukaanada leh in ka badan 35% hoos u dhigista mugga beeryarada laga soo bilaabo bilowga usbuuca 48 waxay ahayd 28.5% kooxda daaweynta marka la barbar dhigo 0% kooxda kantaroolka (P <0.0001). Intaa waxaa dheer, ruxolitinib ayaa sidoo kale hoos u dhigtay calaamadaha guud waxayna si weyn u wanaajisay tayada nolosha bukaanka. Iyada oo ku saleysan natiijooyinka labadan tijaabo caafimaad,ruxolitinibwaxay noqotay dawadii ugu horaysay ee ay ogolaato FDA US daawaynta bukaanada qaba MF.